- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00668434
Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica (ACT FAST)
A Corticosteroid Taper for Acute Sciatica Treatment (The ACT FAST Study)
Study Overview
Detailed Description
Sciatica is most often caused by a herniated disc in the lumbar region of the back and results from inflammation of the nerve roots as they exit the spine. It is a very common cause of back and leg pain, loss of function, and inability to work. Although sciatica is common, the effectiveness of current treatments is limited. Epidural steroid injections (ESIs), which can reduce inflammation of the nerve roots, are commonly used to decrease sciatica pain and restore normal function in patients. The exact effectiveness of ESIs, however, is unknown. If inflammation, and not compression, is the main cause of sciatica, it is reasonable to consider giving the steroid orally rather than by injection. If oral steroids prove effective, patients and clinicians will have access to a simple, inexpensive therapy that can be prescribed by primary care physicians without delay. This study will determine the effectiveness of the oral steroid prednisone in decreasing pain and improving function in people with sciatica.
Participants in this study will attend a screening visit at which they will answer questions about their health to determine eligibility, undergo a neurologic exam, and have a plain lower spine x-ray. An MRI of the lower spine will be performed for those who meet clinical eligibility. Participants whose MRI shows that a disc has ruptured in a specific way will be randomly assigned to receive either a 15-day course of prednisone capsules or a 15-day course of placebo capsules. Participants will take their assigned study medications in addition to their usual pain medications.
At Week 3, participants will return for a follow-up visit during which they will answer questions about their pain and general health and wellness. Participants who are still having considerable pain will be offered an epidural steroid injection (ESI) as a part of the study. At Week 6, participants will be called at home for a telephone interview and again answer questions about their general health and wellness; this telephone call will last about 20 minutes. If they continue to have considerable pain, they will be offered a second ESI as part of the study.
At Week 12, an interviewer will phone participants to determine if their pain has decreased and whether they have been able to return to their normal activities. The telephone contact will last about 20 minutes. Additional information about their back problems will be obtained from their medical records and from Kaiser Permanente's computerized medical records on their use of health care and medicines for back problems. At Week 24, participants will attend an evaluation visit at the Spine Clinic to assess their progress and symptoms. At Week 52 (1 year from randomization), participants will undergo a final telephone interview.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Redwood City, California, United States, 94063
- Kaiser Permanente Northern California, Redwood City
-
Roseville, California, United States, 95661
- Kaiser Permanente
-
San Jose, California, United States, 94119
- Kaiser Permanente Northern California, San Jose
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Seeks care at a Kaiser Permanente clinic spine care specialist at the San Jose, Redwood City, or Roseville site
- Complains of low back pain and functionally incapacitating leg pain extending below the knee with a nerve root distribution
- Score of at least 20 on the modified Oswestry Disability Index
- Appears, in the opinion of the study physician, to be very likely to have a herniated lumbar disc
- MRI study confirms a herniated disc consistent with the signs and symptoms
Exclusion Criteria:
- Onset of sciatica symptoms occurred more than 3 months before study entry
- Cauda equina syndrome
- Active cancer
- Acute spinal fracture
- Currently taking oral steroids
- Diabetes mellitus and taking insulin or glycohemoglobin greater than 10%
- Systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg
- Pregnant or breastfeeding
- Active peptic ulcer disease
- History of intolerance to steroid therapy
- Bleeding diathesis or anticoagulant therapy
- Ongoing litigation or workers compensation claim for low back pain or sciatica
- Underwent previous lumbar surgery
- Received epidural steroid injection (ESI) within the 12 months before study entry
- Unable to read or speak English
- Progressive or severe motor loss
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Prednisone
Participants will receive a 15-day tapering course of prednisone capsules.
|
For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days.
For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
|
Placebo Comparator: Placebo
Participants will receive a 15-day course of placebo capsules.
|
Placebo capsules will look the same as the study medication but will not contain active medicine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oswestry Disability Index, v2
Time Frame: Baseline, Week 3 follow-up
|
The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status.
It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.
|
Baseline, Week 3 follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Numerical Rating Scale
Time Frame: Baseline, Week 3 follow-up
|
Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.
|
Baseline, Week 3 follow-up
|
Oswestry Disability Index, v2
Time Frame: Baseline, Week 52 follow-up
|
The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status.
It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.
|
Baseline, Week 52 follow-up
|
Pain Numerical Rating Scale
Time Frame: Baseline, Week 52 follow-up
|
Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.
|
Baseline, Week 52 follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Harley Goldberg, DO, Kaiser Permanente San Jose Medical Center
- Principal Investigator: Andrew L. Avins, MD, MPH, Kaiser Permanente Division of Research
- Principal Investigator: William Firtch, MD, Kaiser Permanente Redwood City
- Principal Investigator: Mark Tyburski, MD, Kaiser Permanente, Roseville
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Neuromuscular Diseases
- Sciatic Neuropathy
- Mononeuropathies
- Peripheral Nervous System Diseases
- Neuralgia
- Sciatica
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
Other Study ID Numbers
- R01AR053960 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sciatica
-
Prince Sattam Bin Abdulaziz UniversityCompleted
-
University Hospital, MontpellierUnknown
-
Nantes University HospitalTerminatedDiscal SciaticaFrance
-
University of LahoreRecruitingPain | Acute SciaticaPakistan
-
Pakistan Institute of Medical SciencesRiphah International UniversityCompletedSciatica | Sciatica AcutePakistan
-
St George Hospital, AustraliaSt George & Sutherland Medical Research FoundationUnknown
-
Kyung Hee University Hospital at GangdongNational Research Foundation of KoreaUnknownChronic SciaticaKorea, Republic of
-
China Medical University HospitalCompletedBack Pain | Low Back Pain | Low Back Pain, Mechanical | Low Back Pain, Recurrent | Low Back Pain, Postural | Low Back Strain | Lumbago | Lumbago With Sciatica | Lumbago With Sciatica, Unspecified SideTaiwan
-
Assistance Publique - Hôpitaux de ParisCompletedPost Operative Sciatica by Lumbar Spinal FibrosisFrance
-
Centro Universitário Augusto MottaCompletedDisability Evaluation | Manual Therapies | Physical Therapy Modalities | Sciatica Pain
Clinical Trials on Prednisone
-
Merck KGaA, Darmstadt, GermanyCompleted
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingVasculitis | Granulomatosis With Polyangiitis | Wegener GranulomatosisUnited States
-
Rabin Medical CenterUnknown
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS)CompletedMyasthenia GravisThailand, Canada, Germany, Italy, Netherlands, Brazil, United States, Argentina, Australia, Chile, Japan, Mexico, Poland, Portugal, South Africa, Spain, Taiwan, United Kingdom
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaboratorsActive, not recruitingGranulomatosis With PolyangiitisUnited States, Canada
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknown
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
Prof. Tony hayek MDCompletedDiabetes | Atherosclerosis | DyslipidemiasIsrael
-
Health Science Center of Xi'an Jiaotong UniversityUnknownFocal Segmental GlomerulosclerosisChina
-
National Institute for Tuberculosis and Lung Diseases...SuspendedInterstitial Lung Disease | Lung Neoplasm MalignantPoland